Alnylam’s Vutrisiran Receives the US FDA’s Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis

 Alnylam’s Vutrisiran Receives the US FDA’s Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis

Alnylam’s Vutrisiran Receives the US FDA’s Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis

Shots:

  • The US FDA has granted FT designation vutrisiran for treating polyneuropathy of hATTR amyloidosis in adults. The designation allows Alnylam to submit NDA for vutrisiran
  • The P-I study assessing Vutrisiran (quarterly dosing with low-volume, SC) demonstrated a reduction in the burden of care for the disease. The safety & efficacy of the therapy are being evaluated ongoing HELIOS-A and HELIOS-B P-III clinical studies with the anticipated P-III HELIOS-A results in H1’21
  • Vutrisiran (SC) is an investigational, RNAi therapeutic in development for the treatment of ATTR amyloidosis, which encompasses both hereditary (hATTR) and wild-type (wtATTR) amyloidosis

Click here ­to­ read full press release/ article | Ref: Alnylam | Image: Alnylam

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post